Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti-reward

Movement Disorders

Volumn 25, Issue 7, 2010, Pages 867-876

  Evans, Andrew H ^a,b,c   Lawrence, Andrew D ^d   Cresswell, Silke Appel ^e   Katzenschlager, Regina ^c,f   Lees, Andrew J ^c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Donauspital/SMZ Ost ^*  (Austria)

Author keywords

Non motor; Parkinson's disease; Reward; Withdrawal

Indexed keywords

APOMORPHINE; DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPULSIVE PERSONALITY DISORDER; CONTROLLED STUDY; DISEASE DURATION; DOPAMINE DYSREGULATION SYNDROME; DRUG DEPENDENCE; DRUG EFFECT; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; VISUAL ANALOG SCALE;

AFFECT; COMPULSIVE BEHAVIOR; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 77951942661     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22898     Document Type: Article

References (44)

1. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423428. (Pubitemid 30248740)
2. Koob GF. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 2009;56 (Suppl 1):1831.
3. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction 2001;96:103114.
4. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181184.
5. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2:595604.
6. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397405. (Pubitemid 38559642)
7. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:3749.
8. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry 1993;50:975990.
9. Albanese A, Bonuccelli U, Brefel C, et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord 2001;16:197201. (Pubitemid 36049965)
10. de Wit H, Uhlenhuth EH, Pierri J, Johanson CE. Individual differences in behavioral and subjective responses to alcohol. Alcohol Clin Exp Res 1987;11:5259. (Pubitemid 17041824)
11. Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 2002;27:10271035. (Pubitemid 35447639)
12. Powell JH, al-Adawi S, Morgan J, Greenwood RJ. Motivational deficits after brain injury: effects of bromocriptine in 11 patients. J Neurol Neurosurg Psychiatry 1996;60:416421.
13. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intra-rater reliability assessment. Mov Disord 1994;9:390394.
14. Borek LL, Friedman JH. Levodopa addiction in idiopathic Parkinson's disease. Neurology 2005;65:1508. (Pubitemid 41552800)
15. Stein WM, Read S. Chronic pain in the setting of Parkinson's disease and depression. J Pain Symptom Manage 1997;14:255258. (Pubitemid 27415741)
16. Merims D, Galili-Mosberg R, Melamed E. Is there addiction to levodopa in patients with Parkinson's disease? Mov Disord 2000;15:10141016.
17. Muller U, Reuter M, Hermann W, Gertz HJ. Levodopa dependency in Parkinson's disease: case report and review. Nervenarzt 2002;73:887891. (Pubitemid 36062328)
18. Priebe S. Levodopa dependence: a case report. Pharmacopsychiatry 1984;17:109110.
19. Solla P, Floris G, Tacconi P, Cannas A. Paraphilic behaviors in a parkinsonian patient with hedonistic homeostatic dysregulation. Int J Neuropsychopharmacol 2006;12. (Pubitemid 46122775)
20. Tack E, De Cuypere G, Jannes C, Remouchamps A. Levodopa addiction. A case study. Acta Psychiatr Scand 1988;78:356360.
21. Gunal DI, Nurichalichi K, Tuncer N, Bekiroglu N, Aktan S. The clinical profile of nonmotor fluctuations in Parkinson's disease patients. Can J Neurol Sci 2002;29:6164. (Pubitemid 34263586)
22. Racette BA, Hartlein JM, Hershey T, Mink JW, Perlmutter JS, Black KJ. Clinical features and comorbidity of mood fluctuations in Parkinson's disease. J Neuropsychiatry 2002;14:438442. (Pubitemid 35265991)
23. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:14591464.
24. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59:408413. (Pubitemid 34857934)
25. Laurent J, Catanzaro SJ, Joiner TE, Jr, et al. A measure of positive and negative affect for children: scale development and preliminary validation. Psychol Assess 1999;11:326328. (Pubitemid 29449327)
26. Carver CS, Scheier MR. Principles of self-regulation: action and emotion. In: Higgins ET, Sorrentino RM, editors. Handbook of motivation and cognition: foundations of social behavior. New York: Guilford Press; 1990. p352.
27. Barr AM, Markou A, Phillips AG. A crash course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci 2002;23:475482. (Pubitemid 35279609)
28. Maricle RA, Valentine RJ, Carter J, Nutt JG. Mood response to levodopa infusion in early Parkinson's disease. Neurology 1998;50:18901892. (Pubitemid 28283278)
29. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995;45:17571760.
30. Funkiewiez A, Ardouin C, Krack P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003;18:524530. (Pubitemid 36656536)
31. Black KJ, Hershey T, Hartlein JM, Carl JL, Perlmutter JS. Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease. Neuropsychopharmacology 2005;30:590601. (Pubitemid 40271161)
32. Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol 2008;59:2953.
33. al-Adawi S, Powell J. The influence of smoking on reward responsiveness and cognitive functions: a natural experiment. Addiction 1997;92:17731782.
34. Dawkins L, Acaster S, Powell JH. The effects of smoking and abstinence on experience of happiness and sadness in response to positively valenced, negatively valenced, and neutral film clips. Addict Behav 2007;32:425431. (Pubitemid 44918223)
35. Belin D, Jonkman S, Dickinson A, Robbins TW, Everitt BJ. Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction. Behav Brain Res 2009;199:89102.
36. Evans AH, Lawrence AD, Lees AJ. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:267272.
37. Frank MJ, Seeberger LC, O'reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004;306:19401943.
38. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004;17:393398.
39. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61:422423. (Pubitemid 36975988)
40. Steeves TDL, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009;132:1376-1385.
41. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852858. (Pubitemid 43673163)
42. Sher KJ, Trull TJ. Personality and disinhibitory psychopathology: alcoholism and antisocial personality disorder. J Abnorm Psychol 1994;103:92102.
43. Sofuoglu M, Dudish-Poulsen S, Brown SB, Hatsukami DK. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend 2003;69:273282. (Pubitemid 36293939)
44. Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson's disease. Neurology 2007;69:342347. (Pubitemid 47205660)